Navigation Links
Sinovac Files Shelf Registration Statement
Date:11/18/2009

BEIJING, Nov. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "The shelf registration is intended to provide us with greater financial flexibility to execute our growth strategy over the next several years. It is important to note that we do not have immediate plans to raise capital."

If and when the shelf registration statement on Form F-3 is declared effective by the SEC, Sinovac may from time to time offer and sell up to 10 million common shares. The use of the net proceeds from the sale of the common shares will be set forth in the applicable prospectus supplement filed each time common shares are sold.

The registration statement has been filed with the SEC, but has not yet become effective. The terms of any offering under the registration statement would be established at the time of the offering and as required would be described in a prospectus supplement filed with the SEC. The common shares may not be sold, nor may offers to buy the common shares be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell any common shares, or the solicitation of an offer to buy any common shares, nor will Sinovac sell any common shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the laws of any such state or jurisdiction.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and PANFLU.1(TM) (pandemic influenza A (H1N1)).

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

    Helen G. Yang
    Sinovac Biotech Ltd.
    Tel:   +86-10-8289-0088 x9871
    Fax:   +86-10-6296-6910
    Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Janine McCargo
     The Ruth Group
     Tel:   +1-656-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
2. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
3. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
4. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
5. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
6. deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets
7. Derma Sciences Files S-1 Registration Statement
8. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
9. Labopharm files New Drug Submission with Health Canada for novel antidepressant
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
11. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... YORK , Feb. 20, 2017  This report analyzes the ... Million. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Read the full report: http://www.reportlinker.com/p04707127-summary/view-report.html ... period 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/20/2017)... 20, 2017  National Decision Support Company (NDSC) ... company,s CareSelect Imaging platform within the full range ... the technical foundation for MEDITECH sites, through a ... Clinical Decision Support Mechanism through the MEDITECH EHR. ... and support the integration of NDSC,s mechanism, which ...
(Date:2/20/2017)... Feb. 20, 2017   Orion Health ™ ... Amadeus precision medicine platform to the Amazon Web ... over 110 million patient records globally. "We ... big data solutions built on modern, scalable technology," said ... Life Sciences. "The AWS Cloud gives healthcare companies a ...
Breaking Medicine Technology:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data ... has introduced an innovative workstation designed to reduce nursing fatigue while enhancing productivity. ... EHR Workstation offers a lightweight, highly mobile, multi-functional alternative to the limitations of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network offers physicians ... controlled and non-controlled substances plus the ability to manage orders on their desktop ... now accept electronic prescriptions, according to the Office of the National Coordinator of ...
(Date:2/17/2017)... (PRWEB) , ... February 17, ... ... Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — ... are the critical reimbursement questions manufacturers should be asking before selecting an ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
Breaking Medicine News(10 mins):